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patients with type 2 diabetes and nephropathy over 3.4 years. The clinical outcome 
data were based on the results from the RENAAL trial. Direct medical costs referred 
to the purchase costs of losartan and the cost of National Health Service (NHS) hos-
pitalization. The costs were discounted back at an annual rate of 3%. Also sensitivity 
analysis was performed. RESULTS: RENAAL study establishes that losartan, along 
with conventional antihypertensive treatment as needed, confers strong renal protec-
tion in patients with type-2 diabetes and nephropathy. Globally, the total cost over 
42 months of follow-up was estimated at 9.802,49 a in the losartan and a13,405,47 
in the placebo group, resulting into a cost saving of a3602.98 per patient. Results 
were robust to both clinical and economic variables. CONCLUSIONS: In addition to 
the medical beneﬁt, this analysis demonstrated the economic relevance of treatment 
with losartan in type 2 diabetic patients with nephropathy.
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OBJECTIVES: A recently published health technology appraisal (NICE guidance 57) 
on continuous subcutaneous insulin infusion (CSII) therapy considered observational 
studies to complement RCTs in the assessment of effectiveness of CSII in type 1 dia-
betes patients. Observational studies showed signiﬁcantly higher improvements in       
HbA1c levels with CSII compared to multiple daily injections (MDI) as available RCTs       
did. Furthermore, a statistically signiﬁcant decrease of severe hypoglycaemic episodes 
has been stated. Our model based analysis assessed the clinical and economical impact          
in Germany. METHODS: The following baseline assumptions were applied within 
our validated type 1 diabetes model: (1) patient characteristics at simulation start (age 
26 years, duration of diabetes 12 years, baseline HbA1c 8.7%,); (2) a HbA1c improve-
ment by CSII compared to MDI of 0.6% (RCTs) and 1.2% (observational); (3) 
reduction of severe hypoglycemic events by 50%; (4) costs for insulin pumps a3,680 
during an amortization period of 4 years; (5) annual costs for infusion sets a1,040. 
RESULTS: With CSII total life time costs per patient increased by a50,967 / a36,873 
with an HbA1c reduction of 0.6% / 1.2%. Life expectancy increased by 0.99 / 2.00 
years, respectively. In consequence RCTs yield to an incremental cost-effectiveness 
ratio (ICER) of a51,736 and observational studies to a18,359 per life year gained. 
Life time cumulated costs for nephropathy and amputation with CSII compared 
to MDI decreased by a10,787 / a22,967 and a1,183 / a2,462, respectively. 
CONCLUSIONS: The NICE appraisal judged observational data in CSII as better 
resembling the population in routine care. Data derived from observational studies 
indicate that HbA1c-reductions can be distinctly higher than described in RCTs. In 
consequence the ICER could improve considerably. In the underlying analysis the 
additional costs for insulin pump and consumables are partially compensated by the 
reduced complication-related costs due to the improved glycemic control in CSII 
therapy.
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OBJECTIVES: A multicentre, randomised, double-blind, placebo-controlled clinical 
trial was conducted in Japanese impaired glucose tolerance (IGT) population to evalu-
ate the effect of preventing the development of type-2 diabetes mellitus (T2DM), and 
a signiﬁcant effect of voglibose in preventing the development of T2DM was conﬁrmed 
compared to the placebo. The objective of this analysis was to estimate the cost-
 effectiveness of administering voglibose in addition to standard care of diet and exer-
cise compared to standard care alone for high-risk Japanese individuals with IGT. 
METHODS: An annual cycle Markov model was constructed to estimate the long-
term prognosis of individuals with IGT (56-years-old), in terms of expected medical 
costs, and life expectancy. The Markov model consisted of ﬁve stages: normal glucose 
tolerance, IGT, T2DM, dialysis and death. Transition probabilities were derived from 
the results of the voglibose clinical trial as well as the epidemiological information. 
Costs included the drug acquisition cost of voglibose, IGT management cost, annual 
medical costs of T2DM and cost of dialysis. Effectiveness was evaluated by life expec-
tancy. The future costs and effectiveness were discounted by 3% per year. RESULTS: 
Expected lifetime costs for the voglibose administration group and the standard care 
group were calculated at JPY718,724 (a5,380) and JPY1,365,405 (a10,220) respec-
tively, with voglibose administration resulting in an estimated saving of JPY646,681 
(a4,840). Life expectancy was calculated at 18.672 years and 18.073 years respec-
tively, with life expectancy prolonged by 0.599 years when voglibose was administered 
along with the standard care. CONCLUSIONS: In order to prevent T2DM among 
Japanese individuals with IGT, intervention by voglibose together with the standard 
care for life-style modiﬁcation resulted in the expectation of long-term cost-saving, as 
well as prolongation of life expectancy, compared to the standard care of conducting 
only diet and exercise therapies.
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OBJECTIVES: CHD, DMT2 and COPD constitute an enormous burden of disease 
due to high prevalence, severe co-morbidities, increased mortality and high costs for 
society. Smoking is a main risk factor for developing the mentioned diseases and has 
a major impact on the disease development. Aim of the presented study was to analyze 
the incremental cost-effectiveness ratios (ICER) of smoking cessation with NRT com-
pared to Placebo/no intervention for patients with CHD, DMT2 and COPD. 
METHODS: The ICERs were calculated for each study population by use of separate 
Markov-Models. Patient started the models in the age of 45 years and undertake a 
single quit attempt with NRT or Placebo/no intervention. According to the likelihood 
of success, the diseases’ long-term natural courses are simulated for either smokers or 
ex-smokers. Input data such as success rate of smoking quit attempt, transition prob-
abilities, costs (base year 2008) are based on systematic literature researches and 
internal calculations. From the perspective of the German Statutory Health System, 
incremental costs per life-year gained (LYG) are calculated. Assumptions and uncer-
tain parameters are set conservatively and tested in multiple sensitivity analyses. 
RESULTS: Within a simulated time horizon of 55 years, smoking cessation with NRT 
is the dominant strategy: in all indications, NRT leads to additional LYGs at lower 
costs compared to Placebo/no intervention. NRT remains the dominant strategy 
throughout most sensitivity analyses. The parameters of highest inﬂuence on the 
outcome are the effectiveness of both strategies and additionally considered costs for 
smokers. CONCLUSIONS: NRT is a cost-effective treatment option for smoking 
cessation compared to Placebo or no intervention in patients with CHD, diabetes and 
COPD. The results of these analyses are robust to the variation of numerous model 
parameters and assumptions.
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OBJECTIVES: To project long term costs and outcomes for continuous subcutaneous         
insulin infusion (CSII) compared with multiple daily injections (MDI) of insulin in 
adult type-1 diabetes mellitus (T1DM) patients in Italy from the National Health 
Service (NHS) perspective. METHODS: The CORE Diabetes Model (CDM) was used 
to determine the incremental cost-effectiveness ratio (ICER) of CSII compared with 
MDI among adult patients with T1DM in Italy. The primary input variable was 
change in HbA1c and assumed to be a 1.2% improvement for CSII as compared to 
MDI in a cohort of Italian T1DM patients with an average HbA1c baseline value of 
8.95%. It was also assumed that CSII patients had 50% less hypoglycemic events 
compared with MDI patients. A series of Markov constructs simulated the progression 
of diabetes-related complications. The average annual cost for CSII and MDI were 
a5699.20 and a2734.71, respectively. The costs were derived from Italian-speciﬁc 
sources and other published data. A 60-year time horizon and a discount rate of 3.0% 
per annum on costs and clinical outcomes were used. RESULTS: Treatment with CSII 
was associated with improvements in life expectancy of 0.981 years vs. MDI and 
quality adjusted life year (QALY) of 1.063 years vs. MDI with corresponding ICERs 
of a34,541 per life-year and a31,879 per quality-adjusted life year (QALY) gained for 
CSII compared with MDI. The cumulative incidence of end-stage renal disease (ESRD) 
was reduced by 18% (RR  0.816) with a NNT of 22 patients to avoid one case of 
ESRD.while cumulative incidence of peripheral vascular disease (PVD) was reduced 
by 14% (RR  0.856); with a NNT of 46 patients to avoid one case of PVD. CON-
CLUSIONS: Setting the willingness to pay at a40,000/QALY (based on a £30,000 
NICE threshold), CSII is a cost-effective treatment option when compared to MDI for 
adult patients with T1DM in Italy.
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OBJECTIVES: To compare the direct treatment costs in insulin-naïve type-2-diabetics 
(T2D) starting a basal supported oral therapy (BOT) with either insulin glargine (GLA) 
or NPH-insulin (NPH) over 10 years focusing on the different persistence to these 
regimens. METHODS: A cost-minimization approach was applied. The analysis was 
conducted from the German statutory health insurance (SHI) perspective. A Markov 
model was developed simulating the onset of a BOT with GLA or NPH at a ratio of 
1:1 and thereafter switching to an intensiﬁed conventional therapy (ICT) with the 
same basal insulin in the course of 10 years. Persistence data were obtained from the 
IMS Disease Analyzer database [1] considering the ﬁrst 6 months after starting BOT 
as titration phase. Cost data were derived from a German cost evaluation in an 
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ambulatory setting [2] (cost base year 2005). As only costs were considered, no dis-
counting was applied. RESULTS: In the ﬁrst year after initiating a BOT, costs per 
patient are slightly higher (a3.25) in GLA- than NPH-based regimens. From year two 
GLA regimens show an increasing cost advantage compared to NPH up to a1,217 
per patient after 10 years. As all patients have changed to ICT at year 10, a longer 
time horizon would not change the ﬁndings. Calculated for an estimated cohort of 
44,366 German T2D covered by the SHI and starting a BOT with GLA (50%) or 
NPH (50%), the total costs over 10 years are a169.7 vs. a223.7 million, respectively. 
CONCLUSIONS: Due to a longer persistence to a basal supported oral therapy in 
T2D, long-term costs of GLA are lower compared to NPH. Therefore, initiating an 
insulin therapy using BOT with GLA leads to potential cost savings of a54 million 
per 10 years for the German SHI. References: [1] Diabetologie und Stoffwechsel 
2009;4:1–6 [2] J Med Econ 2008;11:695–712.
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OBJECTIVES: To compare resource utilization and costs of type-2 diabetic (T2D) 
patients treated with either insulin glargine (GLA) or insulindetemir (DET) in a basal-
bolus regimen. METHODS: LIVE-COM* was a non-interventional study in 138 
primary care centres in Germany (representative sample). 1731 T2D patients with 
statutory health insurance (SHI) status were enrolled when either treated with GLA 
(n  1150) or DET (n  581) in a basal-bolus regimen for at least 6 months prior to 
documentation. Total direct diabetes treatment costs (DTC) derived from antidiabetic 
medications (insulins, oral drugs) and consumables (test strips, lancets, needles) were 
assessed retrospectively over 6 months. RESULTS: Respective patient characteristics 
(mean) for GLA (53% male) and DET (49% male): age: 66/65 years, BMI: 
31.3/32.7 kg/m², HbA1c: 7.5/7.7%, fasting blood glucose: 140/148 mg/dl, onset of 
diabetes 10 yrs ago: 60/59%, start of insulin therapy 5 yrs ago: 62/64%, number 
of diabetic complications (3.0/2.9). Resource use: Compared to DET, GLA patients 
had on average fewer basal insulin injections per day (1.1 vs. 1.3) and required sig-
niﬁcantly less test strips (3.2 vs. 3.6). Mean daily total insulin dose (basal/bolus) was 
signiﬁcantly lower in GLA (27.7/40.3 U) compared to DET (32.1/47.1 U). Reported 
hypoglycemia, hospitalization rates and frequency of physician contacts did not differ 
between groups. Adjusted mean DTC per patient and 6 months were a932 (GLA) vs. 
a1061 (DET); p  0.001. Adjusted mean single costs (GLA vs. DET) were: basal insulin 
a223/246 (p  0.001), bolus insulin a241/289 (p  0.001), oral drugs a37/36 (ns), test 
strips a347/393 (p  0.001), needles a68/80 (p  0.001), lancets a14/16 (ns). CON-
CLUSIONS: Insulin glargine based basal-bolus regimens resulted in annual cost 
savings of a256 per patient compared to DET regimens from the SHI perspective in 
Germany. GLA patients showed better glycemic control under routine care conditions. 
*Long acting Insulin glargine Versus Insulin detemir cost Evaluation COMparison.
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OBJECTIVES: Cost comparison of insulin glargine (IG) versus insulin detemir (ID) in 
a basal-bolus regime with mealtime insulin aspart in type 2 diabetes patients (T2D) 
in Germany. METHODS: Clinical data were taken from a randomised controlled trial 
[1]. IG was administered once daily, ID once or twice daily. Mean daily insulin doses 
(basal :bolus) were 0.59 and 0.32 U/kg for IG and 0.82 and 0.36 U/kg for ID. Gly-                 
caemic control, weight gain, adverse events and risk of hypoglycaemia were similar 
in both groups after 1 year (non inferiority trial) so a cost minimisation analysis was 
undertaken. Costs were calculated from the perspective of the statutory health insur-
ance (SHI) using ofﬁcial 2008 prices. It was assumed that a new needle, lancet and 
test strip were used at the time of each injection. RESULTS: The annual single costs 
per patient for needles were a393 for IG and a449 for ID. The costs of blood glucose 
test strips and lancets were a1125 for IG and a1286 for ID. The overall costs of 
basal-bolus insulin were a1,607 for IG and a2144 for ID. The total annual costs per 
patient was a3126 for IG compared with a3879 for ID, translating into a 19% annual 
cost saving of a753/patient in favour of IG. Sensitivity analyses conﬁrmed the robust-
ness of the results. CONCLUSIONS: IG and ID basal-bolus regimes have comparative 
safety and efﬁcacy outcomes, based on [1], IG however may represent a signiﬁcantly 
more cost saving option for T2D patients in Germany requiring basal-bolus insulin 
analogue therapy with potential cost savings of a753a (19%) compared to ID. REFER-
ENCE: [1] Hollander P et al.. A 52-week, multinational, open-label, parallel-group, 
noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in 
a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. 
Clinical Therapeutics 2008;30:1976–87. Study supported by sanoﬁ-aventis.
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OBJECTIVES: Different insulin regimes may have different efﬁcacy that can be bal-
anced by higher dosing, which means higher costs. Payers are considered to choose 
the more cost effective therapies, and pay less for the same efﬁcacy results. Aim of 
our study was to determine the cost born on payers reimbursing basal analoge insu-
lines. METHODS: We used two studies were designed to achieve the same clinical 
beneﬁt, such as non-inferiority studies. This way the effectiveness will be the same and 
we could focus on costs only. Dose differences were multiplied with actual Hungarian 
costs of insulins RESULTS: We used an article by Rosenstock compared basal ana-
logue insulins in BOT indication and another article by Hollander done on ICT indica-
tion. In the Rosenstock study patients required an average 31 unit higher daily insulin 
dose on detemir than on glargin, to achieve the same clinical effectiveness as there 
was no signiﬁcant difference in terms of HbA1c levels. Using Hugarian drug costs, 
this higher dose with detemir related to an extra cost of HUF 111,887 per year. The 
case was the same with the Hollander study where detemir patients required on 
average 22.5 unit higher daily dose of basal insulins and 4.3 unit more rapid insulin 
on daily average. In the Hungarian health care system this gives an extra cost of HUF 
94,182 on yearly average. CONCLUSIONS: In clinical trials detemir patients requires 
signiﬁcantly more insulin than glargin patients to achieve the same clinical beneﬁt, 
which would result in a signiﬁcantly higher cost in the Hungarian health care 
system.
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OBJECTIVES: Cost comparison of basal insulin analogues detemir (ID) and glargine 
(IG) in combination with oral antidiabetic drugs (basal supported oral therapy; BOT) 
for type-2 diabetes patients in Germany. METHODS: Clinical data were taken from 
a randomised controlled clinical trial (RCT) [1]. IG was administered once daily, ID 
was administered once (45%) or twice daily (55%). After 52 weeks mean daily ID 
dose was 77% higher (0.78 U/kg) than IG dose (0.44 U/kg). Glycemic control, weight 
gain, adverse events and risk of hypoglycemia were comparable after one year (non 
inferiority trial) so a cost minimisation analysis was undertaken. It was assumed that 
a new needle, lancet, and test strip was used at the time of each injection. Annual 
direct treatment costs were estimated from the perspective of the German statutory 
health insurance (SHI). Simulated resources included medication and consumable 
items. Initial and ﬁnal insulin doses and proportion of patients with once/twice daily 
insulin injection were taken from the RCT. Unit costs were taken from ofﬁcial German 
sources. Deterministic- (DTA) and probabilistic sensitivity analyses (PSA) on resource 
use and unit costs were performed. RESULTS: Average annual treatment costs per 
patient (base case) were a941 for IG and a1406 for ID (annual cost saving a464). 
Single costs of consumable items amounted at a380 (IG) and a588 (ID) respectively. 
Sensitivity analyses conﬁrmed the ﬁndings in favour of glargine. PSA results found 
cost savings could be at least a500 with a probability of ^59%. CONCLUSIONS: 
The current model estimated that IG was associated with lower annual treatment costs 
of a464 (33%) compared to the use of IG. REFERENCE: [1] Rosenstock J et al. A 
randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin 
glargine when administered as add-on to glucose-lowering drugs in insulin-naive 
people with type-2 diabetes. Diabetologia 2008;51:408–16.
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OBJECTIVES: To perform a comparative analysis of the costs linked to the treatment 
with Insulin Glargine (IG) or Insulin Detemir (ID) in type 1 diabetes mellitus patients 
from the Mexican private market perspective. METHODS: Clinical data related to 
each treatment derives from a study performed by Pieber and cols. (2008): a 26-week 
open-label, parallel trial, which compares efﬁcacy and safety of IG and ID both in 
combination with insulin aspart. Primary objective in efﬁcacy was HbA1c and 
hypoglycaemias tolerability. HbA1c control is equivalent in the two regimens, while 
the overall risk of hypoglycaemias had no differences in conﬁrmed hypoglycaemias. 
Patients treated with IG required higher bolus dose, but lower basal and total dose of 
insulin. The cost of each treatment regimen was calculated using the unit cost of             
insulin, needles, and blood glucose tests (BGT). Costs calculations referred to year           
2009 and were derived from published tariffs. Sensitivity analysis was performed using 
a Monte Carlo simulation. RESULTS: Overall, patients treated with ID required 
13.5% more total insulin, and 20% more needles and BGT than IG patients. Manage-
ment with IG has lower total costs than ID, which allows savings of a203 per patient 
in the 26 weeks-period. Savings with IG were related to the costs of total insulin, and 
the lower injections required of basal insulin. Sensitivity analysis showed savings from 
a58 to a651 between the percentiles 25 and 95. CONCLUSIONS: For patients with 
